LLS Pediatric Acute Leukemia (PedAL) Master Clinical Trial

Summary:

Therapeutic options for relapsed AML or some subsets of ALL remain limited. However, recent large-scale discovery efforts using next generation sequencing (NGS) methods have identified recurrent mutations, cellular signaling, and cell surface antigen targets for new therapies. This is a master trial that will screen each relapsed or refractory leukemia patient for standard diagnostic information, complete genomic profiling, molecular diagnostics, immunophenotyping and clinical data in order to match them with a sub-trial with the best available treatment for their disease subtype and parameters above.

Trial Registration: ClinicalTrials.gov Identifier: NCT04726241